紫杉醇联合化疗方案治疗晚期胃癌的临床研究  

Taxol-based chemotherapy in the treatment of advanced gastric cancer

作　　者：李园[1] 武晓勤[1] 崔慧娟[1] 谭煌英[1] 

机构地区：[1]中日友好医院肿瘤科,北京100029

出　　处：《中华肿瘤杂志》2004年第9期562-564,共3页Chinese Journal of Oncology

摘　　要：目的　评价含紫杉醇 (Taxol)化疗方案治疗晚期胃癌的临床疗效和毒性反应。方法　用含紫杉醇联合化疗方案治疗晚期胃癌患者 2 9例 ,包括Taxol+5 Fu 17例 ,Taxol+DDP 10例 ,Taxol +E ADM 2例。结果　可评价疗效者 2 6例 ,无完全缓解 (CR)患者 ,部分缓解 (PR) 10例 ,占 34.5 % ,稳定(SD) 12例 ,占 4 1.4 % ,进展 (PD) 4例 ,占 13.8% ,总有效率 (CR +PR)为 34.5 %。临床受益率为 72 .4 %。中位肿瘤进展期 5 .8个月 ,中位生存期 9.3个月。主要副反应为白细胞减少 2 6例 (89.7% ) ,脱发 2 5例 (86 .2 % ) ,肌肉关节痛 2 3例 (79.3% )等 ,无治疗相关性死亡。结论　以紫杉醇为主的联合化疗方案治疗晚期胃癌患者有效 ,临床缓解率较高 ,明显减轻患者痛苦 ,提高生存质量 ,毒副反应可耐受 。Objective To evaluate the efficacy and toxicity of taxol-based chemotherapy in the treatment of advanced gastric cancer (AGC). Methods Twenty-nine patients with AGC treated with taxol-based protocols: taxol plus 5-fluouracil 17 patients, taxol plus cisplatin 10 patients, taxol plus epirubicin 2 patients. Results Twenty-six patients were evaluated for clinical response. There was no complete response, PR 10 (34.5%), SD 12 (41.4%), PD 4 (13.8%). The total response rate was 34.5%. The clinical beneficial response rate was (72.4%) (21/29). Median time to progression (mTTP) was 5.8 months and median overall survival time was 9.3 months. The main side effects were: suppression of bone marrow in 26 patients ((89.7%)), alopecia in 25 ((86.2%)), myodynia and arthrodynia in 23 (79.3%). There was no death during the treatment. ConclusionTaxol-based chemotherapy is an effective and well tolerated regimen in the treatment of AUC, which can relieve suffering and improve quality of life of the patients. It can be used as the second-line therapy for relapsed advanced gastric cancer.

关 键 词：治疗 晚期胃癌 联合化疗方案 紫杉醇 患者 PR 临床 结论 目的 方法 

分 类 号：R735.2[医药卫生—肿瘤]